Literature DB >> 7862975

Cost-effectiveness of MR angiography in cases of limb-threatening peripheral vascular disease.

D Yin1, R A Baum, J P Carpenter, C P Langlotz, M J Pentecost.   

Abstract

PURPOSE: To evaluate the cost-effectiveness of magnetic resonance (MR) angiography in the preoperative planning of treatment in patients with limb-threatening peripheral vascular disease (PVD).
MATERIALS AND METHODS: A decision model was developed to study the effects of MR angiography on the outcome and cost of treatment. The authors calculated the incremental cost per quality-adjusted life-years gained (ie, cost-effectiveness ratio) when conventional angiography was replaced or supplemented with MR angiography. Previously reported data regarding the accuracies of MR and conventional angiography were used in the analysis.
RESULTS: The cost-effectiveness ratio of MR angiography ranged from negative (cost-reducing) values to $78,000. For the base case in which the sensitivity and specificity of MR angiography for the evaluation of inflow vessels were 92% and 88% and those of conventional angiography were 97% and 97%, respectively, the cost-effectiveness ratio was $25,895.
CONCLUSION: MR angiography may be a cost-effective alternative to conventional angiography in patients with limb-threatening PVD if its accuracy for the inflow evaluation reaches certain thresholds. Further prospective investigation is warranted.

Entities:  

Mesh:

Year:  1995        PMID: 7862975     DOI: 10.1148/radiology.194.3.7862975

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  The use of QALY and non-QALY measures of health-related quality of life. Assessing the state of the art.

Authors:  M Deverill; J Brazier; C Green; A Booth
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

2.  Evaluation of meglumine gadoterate-enhanced MR angiography (MRA) compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease: a pooled analysis of data from two clinical trials.

Authors:  D J Shah; T-H Lim
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

Review 3.  Methods for measuring temporary health States for cost-utility analyses.

Authors:  Davene R Wright; Eve Wittenberg; J Shannon Swan; Rebecca A Miksad; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 4.  Outcomes research and cost-effectiveness analysis in radiology.

Authors:  M G Hunink
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

5.  Quality-of-life assessment of fibroid treatment options and outcomes.

Authors:  Fiona M Fennessy; Chung Yin Kong; Clare M Tempany; J Shannon Swan
Journal:  Radiology       Date:  2011-03-01       Impact factor: 11.105

6.  Evaluation of contrast-enhanced magnetic resonance angiography (MRA) using Gd-DOTA compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease.

Authors:  Joon-Won Kang; Tae-Hwan Lim; Choong-Gon Choi; Gi-Young Ko; Jeong-Kon Kim; Tae-Won Kwon
Journal:  Eur Radiol       Date:  2010-04-21       Impact factor: 5.315

7.  Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing.

Authors:  J Shannon Swan; Jun Ying; James Stahl; Chung Yin Kong; Beverly Moy; Jessica Roy; Elkan Halpern
Journal:  Qual Life Res       Date:  2010-04       Impact factor: 4.147

Review 8.  Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease.

Authors:  Eoin Moloney; Joanne O'Connor; Dawn Craig; Shannon Robalino; Alexandros Chrysos; Mehdi Javanbakht; Andrew Sims; Gerard Stansby; Scott Wilkes; John Allen
Journal:  Pharmacoecon Open       Date:  2019-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.